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Abstract: Background/Objective: Recent literature has identified links between vitamin B12 deficiency and depres-
sion.We compared the clinical response of SSRI-monotherapy with that of B12-augmentation in a sample of depressed 
patients with low normal B12 levels who responded inadequately to the first trial with the SSRIs.  
Methods: Patients with depression and low normal B12 levels were randomized to a control arm (antidepressant only) or 
treatment arm (antidepressants and injectable vitamin B12 supplementation).  
Results: A total of 199 depressed patients were screened. Out of 73 patients with low normal B12 levels 34 (47%) were 
randomized to the treatment group while 39 (53%) were randomized to the control arm. At three months follow up 100% 
of the treatment group showed at least a 20% reduction in HAM-D score, while only 69% in the control arm showed at 
least a 20% reduction in HAM-D score (p<0.001). The findings remained significant after adjusting for baseline HAM-D 
score (p=0.001).  
Conclusion: Vitamin B12 supplementation with antidepressants significantly improved depressive symptoms in our co-
hort. 
Keywords: Depression, vitamin B12, antidepressants, RCT. 
INTRODUCTION 
 Major Depressive Disorder is an important global public 
health problem associated with the significant burden and is 
projected to be the second leading cause of disability by 
2020 [1]. Prevalence figures worldwide range between 4.2 – 
17% and a systematic review of studies from Pakistan gave 
the estimates as high as 34% for anxiety and depressive dis-
orders [2]. Clinical guidelines recommend the use of SSRIs 
as first-line treatment [3]. Remission rates in the acute phase 
of treatment are 30-40% and an overall 30% show poor re-
sponse to anti-depressant monotherapy [4-6]. In such cases, 
addressing other co-morbid conditions is suggested in addi-
tion to upgrading or augmenting anti-depressant doses [3]. 
 Pakistan, a developing country of 17 million people, is 
fraught with poverty, inadequate nutrition and underprivi-
leged health systems. Several small-case studies from Paki-
stan show vitamin deficiencies to be common [7,8]. A small 
study from Islamabad on a clinical population of patients 
with megaloblastic anemia reported figures of 76% with vi-
tamin B12 deficiency [9]. Although no large scale studies on 
general population are available here, studies from neigh- 
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boring countries that share the culture and climate show vi-
tamin deficiencies to be common [10-12]. A study on a 
healthy Indian population showed the prevalence of B12 
deficiency to be 47% [13]. 
 Vitamin B12 plays an important role in DNA synthesis 
and neurological function. Its deficiency is associated with 
hematological, neurological and psychiatric manifestations 
of which the latter includes irritability, personality change, 
depression, dementia and rarely, psychosis [14]. Recent lit-
erature has identified the links between this vitamin defi-
ciency and depression. High B12 levels in serum are associ-
ated with good treatment response, high homocysteine levels 
which are common in folate / B12 deficiency and in those 
suffering from depression are associated with poor response 
to anti depressant treatment [15-17]. Hyperhomocysteinemia 
may have direct effects on neurotransmitters implicated in 
depression [18].  
 Randomized trials have shown that folate and other nutri-
tional supplementations have a significant effect in treating 
the treatment-resistant depression [19,20]. Folate deficiency 
has also been linked with the delay in treatment response as 
well as relapse [21,22].  
 To date no adequately designed trial compares anti-
depressant monotherapy with B12 augmentation. We aimed 
to compare the clinical response of antidepressants mono-
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therapy with that of B12-augmentation in a sample of de-
pressed patients with low normalB12 levels (190 pg/ml to 
300 pg/ml). 
METHODS 
 The study was designed as an open label randomized 
controlled trial (clinical trials registration number (Clinical 
Trials.gov ID NCT00939718). Patients were enrolled from 
outpatient clinics of the department of Psychiatry at Aga 
Khan University Hospital, Karachi Pakistan from December 
2009 - June 2010. Depression was defined as Patients scor-
ing ≥ 16 on the 20-item Hamilton Rating Scale for Depres-
sion-Urdu version (HAM-D) [23,24]. 
 Low normal B12 level was defined as B12 level ranging 
between 190 and 300 pg/ml. Patients with B12 deficiency 
(level below190 pg/ml) were not enrolled due to ethical rea-
sons (patients with established B12 deficiency must be 
treated and not subjected to randomization). 
Ethics Statement 
 A study protocol was approved by the Ethics Review 
Committee of Aga Khan University hospital. All patients 
signed an informed consent form.  
Randomization and Masking 
 Patients with depression and low normal B12 levels were 
randomized by a computer program into the control arm (an-
tidepressants only) or treatment arm (antidepressants and 
injectable vitamin B12 supplementation). The randomization 
was carried out using a Microsoft Excel spreadsheet using 
the function “RAND” to generate uniform random numbers.  
 The randomized assignment was determined by partition-
ing the range of the random number. Randomization was not 
concealed for investigators. Antidepressants that were pre-
scribed included either a tricyclic antidepressant (TCA) with 
a dose equivalent of imipramine 100 mg to 250 mg/ day and 
the SSRIs dose equivalent of Fluoxetine 20 – 40 mg/day. 
Patients with concurrent unstable medical illness, history of 
manic episodes or psychotic illness, psychotic symptoms in a 
depressive episode, concurrent substance misuse and patients 
with suicidal ideation were excluded. Participants in the con-
trol arm only received the antidepressants. Those in the 
treatment arm received B12 intramuscular injectable as 1000 
mcg every week during the 6 weeks in addition to the anti-
depressants. 
 Any adverse effects of oral medications and injections 
(B12) were monitored and documented on an adverse effects 
sheet in the patient folder.  
 A decline in HAM-D score of 20% or more from the 
baseline, indicating an improvement in depression, was de-
fined as the primary outcome. The total change in HAM-D 
score from baseline to follow up was defined as a secondary 
outcome. Additional secondary outcomes included the fol-
low up HAM-D score and a reduction in HAM-D score of 
50`                                                                                                                                                                                                                     
or more from the baseline. Follow up of the HAM-D score 
was recorded during 12 weeks by a research officer who was 
unaware of the patient’s randomization. 
Statistical Considerations 
 A total of 248 patients equally allocated to the two 
groups provides at least 90 percent power, with a 5 percent 
type I error rate, using a two-sided hypothesis test. This cal-
culation assumes an anticipated difference in the response 
rate of 20 percent between the two groups with a 30 percent 
response rate in the SSRI group and at least a 50 percent 
response rate in the combination treatment group. Consider-
ing a 15 percent dropout rate in each group, an additional 
sample of 44 patients equally divided into the two groups 
would be needed to yield a total required sample size of 292 
patients. Therefore, the target sample size for each arm was 
146. 
 Descriptive statistics were prepared for all characteristics 
including means and standard deviations for continuous 
measures and frequencies and percentages for categorical 
measures. Chi-square or Fisher’s exact tests were used to 
compare categorical baseline characteristics. Two-sample t 
tests were used to compare continuous baseline characteris-
tics. Chi-square tests were used to examine the association 
between treatment and the 20% and 50% reductions in 
HAM-D outcomes. These analyses were extended to logistic 
regression to adjust for the baseline HAM-D score. Two-
sample t tests were used to examine the association between 
treatment and the follow up HAM-D score or change in 
HAM-D score from baseline to follow up. These analyses 
were extended to analysis of covariance to adjust for the 
baseline HAM-D score. All hypotheses tests were two-sided 
and p-values less than 0.05 were considered statistically sig-
nificant. Analyses were conducted using SAS Version 9.2 
(SAS Institute, Inc., Cary, NC, USA). 
Results 
 A total of 199 depressed patients were screened for the 
B12 levels. Vitamin B12 deficiency was present in 44 (22%) 
patients; 73 (36%) had low normal B12 levels and 82 (42%) 
had normal B12 levels. Patients with low B12 levels were 
given the prescriptions for B12 replacement therapy in addi-
tion to the antidepressants. These patients were not random-
ized. Out of 73 patients with low normal B12 levels 34 
(47%) were randomized to the treatment group while 39 
(53%) were randomized to the control arm. There were no 
significant differences between the two groups at baseline 
except for the higher depression scores in the treatment 
group (Table 1). No adverse effects or complications were 
noted in either group. For the primary outcome of 20% re-
duction in HAM-D score, significantly more subjects from 
the treatment group showed a 20% reduction unadjusted for 
baseline HAM-D score (100% vs. 69%; p < 0.001). Examin-
ing a50% reduction from baseline, this effect remained sig-
nificant (44% vs. 5%; p < 0.001). We also adjusted the 
analyses of reduction for the baseline HAM-D score and our 
findings remained significant (Table 2). Additionally, the 
change in HAM-D score was significantly greater for the 
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treatment group, unadjusted and adjusted for the baseline 
HAM-D score (Table 2). 
DISCUSSION 
 Coexistence of depression and vitamin B12 deficiency 
are not uncommon. These patients are routinely treated with 
SSRI and B12 supplementation, however it is not well estab-
lished whether the people with low normal B12 and co-
occurring depression should also receive B12 supplementa-
tion. Our study tried to address this issue. Despite not attain-
ing the targeted sample size, the findings appear significant. 
Vitamin B12 deficiency was present in 22% of our depressed 
population. This frequency is high in a non-vegetarian, rela-
tively young, middle to upper income population of our pa-
tients. A recent study of healthy adults from Karachi showed 
a population based prevalence of vitamin B12 deficiency 
(less than 200 pg/ml) in 9.74% people [25]. These findings 
indicate a substantial co-morbidity of B12 deficiency (22%) 
in our depressed patient population.  
 To our knowledge, this is the first randomized control 
trial in Pakistani population which has looked at clinically 
depressed patients with low B12 levels. We did not random-
ize B12 deficient patients due to ethical reasons. Low normal 
B12 levels were present in 36% of patients. These patients 
are often not treated with B12 supplementation. The findings 
of our study clearly indicate that these patients demonstrated 
significant improvement with B12 supplementation in addi-
tion to SSRI as compared to the control group even after 
adjustment for baseline HAM-D score. We think that these 
patients represent sub group within the clinically depressed 
population and a supplementation with B12 along with the 
conventional antidepressants may be a useful strategy in the 
treatment of depression in such cases.  
 We did not give sham injections to the control group. A 
placebo response due to injections may be responsible for 
the significant improvement in the treatment group. We also 
did not look at differences in response at specific doses of 
antidepressants nor did we stratify our groups on the basis of 
type of antidepressants prescribed. We also could not reach 
our sample size because we were not able to get another ex-
tension in our grant. Due to financial constraints we were not 
able to obtain final B12 levels. These are some of the limita-
tions of our study. However, these findings have important 
clinical implications. B12 deficiency and low normal B12 
levels are common and may be associated with depression 
and the inadequate response to antidepressant treatment in 
patients with depression. Vitamin B12 supplementation with 
antidepressants has significantly improved depressive symp-
toms in our group. Larger, multi-center studies are required 
to extend and replicate our findings. 
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Table. 1. Baseline Characteristics Shown as Mean ± Standard Deviation or Frequency (Percent) 
 Treatment (n=34) Control (n=39) p-value 
Age, in years 37.68 ± 13.38 36.56 ± 12.28 0.71 
Total HAM-D  23.21 ± 5.85 19.38 ± 5.70 0.006 
Vitamin B12 level 238.49 ± 33.21 245.16 ± 27.82 0.36 
Gender    
Male 18 (52.9) 20 (51.3) 0.89 
Female 16 (47.1) 19 (48.7)  
Marital status    
Single never married 9 (26.5)  13 (33.3) 0.84 
Married 21 (61.8)  21 (53.9)  
Divorced/separated/widowed 4 (11.8) 5 (12.8)  
Table 2. Outcomes for Follow Up After 3 Months Shown as Mean ± Standard Deviation or Frequency (Percent) 
 Treatment (n=34) Control (n=39) Unadjusted P-value Adjusted* P-value 
20% reduction in HAM-D score 34 (100) 27 (69.2) <0.001 0.001 
50% reduction in HAM-D score 15 (44.1) 2 (5.1) <0.001 <0.001 
Follow up HAM-D score 12.12 ± 5.12 14.38 ± 4.73 0.053 <0.001 
Change in HAM-D score 11.09 ± 4.58 5.00 ± 3.38 <0.001 <0.001 
Vitamin B12 Supplementation in Treating Major Depressive Disorder The Open Neurology Journal, 2013, Volume 7    47 
ACKNOWLEDGEMENT 
 Authors would like to acknowledge Michele Shaffer PhD 
from School of Public Health, Penn State University for her 
valuable input in statistical analysis and manuscript revision. 
FUNDING 
 Study funding was supported by University research 
council grant of Aga Khan University (G&C code; 70210) 
REFERENCES 
[1] Murray C, Lopez A. The global burden of diseases: a comprehen-
sive assessment of  Mortality and disability from diseases, injuries 
and risk factors in 1990 and projected to 2020. Boston: Harvard 
School of Public Health, WHO and World Bank 1996. 
[2] Mirza I, Jenkins R. Risk factors, prevalence, and treatment of anxi-
ety and depressive disorders in Pakistan: systematic review. BMJ 
2004; 328; 794-8 
[3] American Psychiatric Association; Practice Guideline for the 
Treatment of Patients With Major Depressive Disorder, 3rd ed. 
DOI10.1176/appi.books.9780890423387.654001 
[4] Thase ME, Entsuah AR, Rudolph RL. Remission rates during 
treatment with Venlafaxine or selective serotonin reuptake inhibi-
tors. Br J Psychiatry 2001;178: 234 -41 
[5] Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacip-
ran;a new serotonin and Noradrenaline reuptake inhibitor: an over-
view of its antidepressant activity and clinical tolerability. Int Clin 
Psychopharmacol 1997; 12(2):99-108. 
[6] Antai-Otong, D . Monotherapy Antidepressant: A Thing of the Past 
Implications for the Treatment of Major Depressive Disorder. 
Perspect Psych Care 2007: 43(3): 142-5 
[7] Shah RA, Qureshi MB, Khan AA. Magnitude of vitamin A defi-
ciency in poor communities of the four selected districts of Punjab 
CONSORT 
2010 Flow 
Diagram 
Assessed for eligibility (n=199) 
Excluded  (n=126) 
   Not meeting inclusion criteria (n=126) 
   Declined to participate (n= 0) 
   Other reasons (n=0) 
Analysed (n=39) 
 Excluded from analysis (n= 0) 
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (n=0) 
Allocated to control group (n=39) 
 Received allocated intervention (n= 39) 
 Did not receive allocated intervention (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (n=0) 
Allocated to intervention group (n= 34) 
 Received allocated intervention (n=34) 
 Did not receive allocated intervention (give r 
(n= 0) 
Analysed (n=34) 
 Excluded from analysis  (n=0) 
Allocation 
Analysis 
Follow‐Up 
Randomized (n=73) 
Enrollment 
 
*Adjusted for baseline difference in HAMD scores in the two groups 
48     The Open Neurology Journal, 2013, Volume 7 Syed et al. 
using – (rapid assessment technique). Ann King Edward Med Coll 
2005; 11(3): 314-8 
[8] Khan RM, Iqbal P. Deficiency of vitamin C in South Asia. Pak J 
Med Sci 2006; 22(3): 347-55 
[9] Hashim H, Tahir F. Frequency of vitamin B12 and folic acid defi-
ciencies among patients with megaloblastic anemia. Ann Pak Inst 
Med Sci 2006; 2(3): 192-4  
[10] Yajnik CS, Deshpande SS, Lubree HG, et al. Vitamin B12 defi-
ciency and hyperhomocysteinemia in rural and urban Indians. J 
Assoc Physicians India 2006; 54: 775-82 
[11] Fakhrzadeh H, Ghotbi S, Pourebrahim R, et al. Total plasma ho-
mocysteine, folate, and vitamin b12 status in healthy Iranian adults: 
the Tehran homocysteine survey (2003–2004)/a cross – sectional 
population based study. BMC Public Health 2006; 6: 29 
[12] Lim HS, Heo YR. Plasma total homocysteine, folate, and vitamin 
B12 status in Korean adults. J Nutr Sci Vitaminol (Tokyo) 2002; 
48(4): 290-7  
[13] Refsum H, Yajnik CS, Gadkari M, et al. Hyperhomocysteinemia 
and elevated methylmalonic acid indicate a high prevalence of co-
balamin deficiency in Asian Indians. Am J Clin Nut 2001; 74(2): 
233-241 
[14] Robert C, Brown DL. Vitamin B12 Deficiency. Am Fam Physician 
2003; 67: 979-86. 
[15] Hintikka J, Tolmunen T, Tanskanen A, Viinamäki H. High vitamin 
B12 level and good treatment outcome may be associated in major 
depressive disorder. BMC Psychiatry 2003; 3:17-22 
[16] Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, 
Breteler MM. Vitamin B12, folate, and homocysteine in depres-
sion: the Rotterdam Study. Am J Psychiatry 2002; 159(12): 2099-
01 
[17] Sachdev PS, Parslow RA, Lux O, et al. Relationship of homocys-
teine, folic acid and vitamin B12 with depression in a middle- aged 
community sample. Psychol Med. 2005; 35(4): 529-38. 
[18] Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Rey-
nolds EH: Homocysteine, folate, methylation, and monoamine me-
tabolism in depression. J Neurol Neurosurg Psychiatry 2000: 69; 
228-232 
[19] Alpert JE, Mischoulon D. “Folinic acid (Leucovorin) as an adjunc-
tive treatment for SSRI-refractory depression. Ann Clin Psychiatry 
2002; 14(1): 33-8  
[20] Fava M, Borus JS. “Folate, vitamin B12 and homocysteine in ma-
jor depressive disorder”. Am J Psychiatry 1997; 154(3): 426-8 
[21] Papakostas GI, Peterson T. “Serum folate, vitamin B12, and homo-
cysteine in major depressive disorder, Part I: predictors of clinical 
response in fluoxetine-resistant depression”. J Clin Psychiatry 
2004; 65(8): 1090-5 
[22] Papakostas GI, Peterson T. Serum folate, vitamin B12, and homo-
cysteine in major depressive disorder, Part II: predictors of clinical 
response in fluoxetine-resistant depression. J Clin Psychiatry 2004; 
65(8): 1096-8 
[23] Hamilton M. A rating scale for depression. J Neurol Neurosurg 
Psychiatry 1960; 23: 56-62 
[24] Chaudhry HR, Qureshi Z, Tareen IA, Yazdani I. Efficacy and tol-
erability of Paroxetine 20 mg daily in the treatment of depression 
and depression associated anxiety. J Pak Med Assoc. 2002; 52(11): 
518-25 
[25] Yakub M, Iqbal MP, Kakepoto GN, et al. High prevalence of mild 
hyperhomocystienemia and folate, B12 and B6 deficiencies in an 
urban population in Karachi, Pakistan. Pak J Med Sci 2010; 26 (4): 
923-929. 
 
 
Received: June 28, 2013 Revised: September 06, 2013 Accepted: September 08, 2013 
 
© Syed et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/lic-
enses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. 
